Liquidia (NASDAQ:LQDA – Get Free Report)’s stock had its “buy” rating reiterated by equities researchers at Needham & Company LLC in a research report issued on Tuesday, Benzinga reports. They currently have a $18.00 target price on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 187.08% from the company’s current price.
LQDA has been the subject of a number of other reports. BTIG Research decreased their target price on Liquidia from $20.00 to $18.00 in a report on Thursday, July 6th. Wedbush reissued an “underperform” rating and set a $3.00 price objective on shares of Liquidia in a research report on Monday, August 14th. Finally, HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of Liquidia in a research note on Friday, August 11th.
Liquidia Stock Performance
Liquidia stock opened at $6.27 on Tuesday. The company’s 50 day simple moving average is $7.15 and its 200-day simple moving average is $7.45. Liquidia has a 1 year low of $4.35 and a 1 year high of $9.95. The company has a market capitalization of $405.92 million, a price-to-earnings ratio of -8.14 and a beta of 0.03.
Liquidia (NASDAQ:LQDA – Get Free Report) last released its earnings results on Thursday, August 10th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.19). Liquidia had a negative net margin of 285.82% and a negative return on equity of 62.10%. The firm had revenue of $4.79 million during the quarter, compared to analyst estimates of $4.76 million. Equities analysts expect that Liquidia will post -0.92 earnings per share for the current year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the business. Tower Research Capital LLC TRC increased its stake in Liquidia by 101.3% in the second quarter. Tower Research Capital LLC TRC now owns 7,004 shares of the company’s stock valued at $55,000 after purchasing an additional 3,524 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new position in shares of Liquidia in the 2nd quarter valued at $55,000. UBS Group AG raised its stake in Liquidia by 134.0% during the 2nd quarter. UBS Group AG now owns 7,948 shares of the company’s stock worth $35,000 after acquiring an additional 4,552 shares in the last quarter. Legal & General Group Plc purchased a new stake in Liquidia in the second quarter valued at $38,000. Finally, BNP Paribas Arbitrage SNC boosted its stake in Liquidia by 20.5% in the first quarter. BNP Paribas Arbitrage SNC now owns 9,993 shares of the company’s stock valued at $69,000 after acquiring an additional 1,702 shares in the last quarter. 45.03% of the stock is owned by institutional investors and hedge funds.
Liquidia Company Profile
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension.